

RHINOMED RECEIVES \$425k R&D TAX INCENTIVE REFUND

- Rhinomed has received \$424,967 through the R&D Tax Incentive
- Funds will be used for working capital requirements of the business

16th February, 2022: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF) a global leader in wearable nasal and respiratory technology is pleased to announce that the Australian Taxation Office has refunded the R&D tax incentive amount in respect of the FY21 income tax year.

The Company had previously lodged an application with AusIndustry which was approved. The Company then submitted its FY21 tax return, detailing the R&D tax incentive refund amount.

The Company will use the proceeds for working capital requirements of the business.

This ASX release has been approved for release by the Board of Directors.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

Rhinomed Global (<https://www.rhinomed.global>) is an Australian-based medical technology company with a patented nasal technology platform whose first products are used by consumers in the global sleep, respiration, and nasal congestion markets. These products, sold at major US retailers, support the development, acceptance, and adoption of a pipeline of future wearable, sensor, diagnostic, and drug delivery opportunities. The company has recently secured TGA and FDA class 1 registration for its Rhinoswab, a dual nostril swab designed to collect nasal specimens for diagnostic testing for respiratory diseases, particularly COVID-19.

Since its formation seven years ago, Rhinomed has built the necessary foundation to accelerate its already increasing revenue growth. The company trades on the **ASX:RNO** and the **OTCQB:RHNMF**.

**All financial figures contained in this Announcement are provided on an unaudited basis and are in \$AUD*